Targeting triple-negative breast cancer: optimising therapeutic outcomes

被引：143
作者：
Gelmon, K. [1 ,2 ]
Dent, R. [3 ,4 ]
Mackey, J. R. [5 ,6 ]
Laing, K. [7 ,8 ]
McLeod, D. [9 ]
Verma, S. [10 ,11 ]
机构：
[1] Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E6, Canada
[2] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[3] Natl Canc Ctr, Singapore, Singapore
[4] Duke NUS Grad Med Sch Singapore, Off Clin Sci, Singapore, Singapore
[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[6] Cross Canc Inst, Dept Med Oncol, Edmonton, AB T6G 1Z2, Canada
[7] Mem Univ Newfoundland, Dept Med, St John, NF, Canada
[8] Eastern Hlth, Canc Care Program, St John, NF, Canada
[9] Kaleidoscope Strateg, Toronto, ON, Canada
[10] Univ Toronto, Dept Med, Toronto, ON, Canada
[11] Sunnybrook Hlth Sci Ctr, Dept Med, Div Med Oncol Hematol, Toronto, ON M4N 3M5, Canada
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷 / 09期
关键词：
basal like; breast cancer; cancer treatment; targeted therapy; triple negative; systematic review; PACLITAXEL PLUS BEVACIZUMAB; ENDOTHELIAL GROWTH-FACTOR; BASAL-LIKE SUBTYPE; PHASE-II; PROGESTERONE-RECEPTOR; NEOADJUVANT CHEMOTHERAPY; PRECLINICAL MODELS; 1ST-LINE TREATMENT; ESTROGEN-RECEPTOR; RANDOMIZED-TRIAL;
D O I：
10.1093/annonc/mds067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with targeted and platinum-based therapies. Our review identified TNBC studies of agents with different mechanisms of action, including induction of synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. Combining targeted agents with chemotherapy in TNBC produced only modest gains in progression-free survival, and had little impact on survival. Six TNBC subgroups have been identified and found to differentially respond to specific targeted agents. The use of biological preselection to guide therapy will improve therapeutic indices in target-bearing populations. Ongoing clinical trials of targeted agents in unselected TNBC populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target-selected populations.
引用
收藏
页码：2223 / 2234
页数：12
相关论文
共 119 条
[81]   Basal-like subtype and BRCA1 dysfunction in breast cancers [J].
Miyoshi, Yasuo ;
Murase, Keiko ;
Oh, Koushi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (05) :395-400
[82]   Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 [J].
Moreno-Aspitia, Alvaro ;
Morton, Roscoe F. ;
Hillman, David W. ;
Lingle, Wilma L. ;
Rowland, Kendrith M., Jr. ;
Wiesenfeld, Martin ;
Flynn, Patrick J. ;
Fitch, Tom R. ;
Perez, Edith A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :11-15
[83]   Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction [J].
Morris, Patrick G. ;
Dickler, Maura ;
McArthur, Heather L. ;
Traina, Tiffany ;
Sugarman, Steven ;
Lin, Nancy ;
Moy, Beverly ;
Come, Steven ;
Godfrey, Laura ;
Nulsen, Benjamin ;
Chen, Carol ;
Steingart, Richard ;
Rugo, Hope ;
Norton, Larry ;
Winer, Eric ;
Hudis, Clifford A. ;
Dang, Chau T. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6117-6123
[84]   Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J].
Nielsen, TO ;
Hsu, FD ;
Jensen, K ;
Cheang, M ;
Karaca, G ;
Hu, ZY ;
Hernandez-Boussard, T ;
Livasy, C ;
Cowan, D ;
Dressler, L ;
Akslen, LA ;
Ragaz, J ;
Gown, AM ;
Gilks, CB ;
van de Rijn, MV ;
Perou, CM .
CLINICAL CANCER RESEARCH, 2004, 10 (16) :5367-5374
[85]   Determinants of rapamycin sensitivity in breast cancer cells [J].
Noh, WC ;
Mondesire, WH ;
Peng, JY ;
Jian, WG ;
Zhang, HX ;
Dong, JJ ;
Mills, GB ;
Hung, MC ;
Meric-Bernstam, F .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :1013-1023
[86]  
O'Shaughnessy J, 2007, BREAST CANCER RES TR, V106, pS32
[87]  
O'Shaughnessy J, 2009, CANC RES, P69
[88]  
O'Shaughnessy J, 2011, J CONTRACEPT FERTIL, P29
[89]  
O'Shaughnessy J, 2010, CANC RES, V70
[90]  
O'Shaughnessy J, 2009, J CONTRACEPT FERTIL, P27
3456789101112